LOTTE Holdings, Co., Ltd. (Tokyo, Japan) announced an investment in Physiologas Technologies, a pioneering Japanese medical device company developing next-generation hemodialysis system aimed at transforming chronic kidney disease care.
Founded in 2020, Physiologas is a preclinical stage medical device company that is developing a compact, easy-to-use, at-home hemodialysis device equipped with proprietary dual adsorption filters, in-line ion monitoring, and remote physician monitoring capabilities. With its innovative approach to dialysate regeneration and toxin removal, Physiologas eliminates the need for conventional water infrastructure, making dialysis more accessible and flexible for patients that seek solutions to current chronic kidney disease treatments.
The investment from LOTTE Holdings Healthcare and Biopharmaceutical CVC marks its first investment in the medical device sector, underscoring its commitment to expanding into high-impact healthcare technologies, as well as biopharmaceuticals. This investment round, led by LOTTE Holdings, will support Physiologas in finalizing its prototype, conducting preclinical testing, and preparing for regulatory consultations with PMDA and FDA. The company aims for device approval in Japan by 2029, with subsequent launches planned globally.
The investment in Physiologas is aligned with LOTTE Holdings’ enduring commitment to advancing healthcare innovation and addressing global health challenges. Chronic kidney disease (CKD), which affects over 800 million people worldwide, remains one of the leading causes of mortality – particularly among patients without access to dialysis or transplantation. By supporting Physiologas, LOTTE Holdings aims to democratize CKD treatment and make a meaningful social impact through the development of accessible, next-generation hemodialysis solutions, while enhancing its healthcare portfolio with medical device innovations.
“We believe Physiologas Technologies has the potential to revolutionize conventional hemodialysis with its simple yet truly innovative technology, providing global solutions and improving the quality of life for CKD patients worldwide”, said Managing Partner Dr. Joon Paek from LOTTE Holdings CVC.